MOH
Molina Healthcare, Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Last price
202.20
▲ 5.26 (2.67%)
MARKET · —
Price
Open
196.94
Prev close
196.94
Day high
203.47
Day low
198.01
Volume
473.72K
Market cap
$10.46B
P/E (TTM)
1,251.81
52W range
121.06 – 244.89
Trailing performance
Returnvs SPY
1W
-5.71%
-4.3%
1M
0.00%
-3.7%
3M
+10.50%
+7.4%
6M
+32.64%
+21.6%
YTD
+15.41%
+3.1%
1Y
+15.37%
-4.6%
3Y
-36.31%
-110.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$10.46B
Enterprise value$5.49B
Revenue (TTM)$42.47B
Gross profit$3.58B
EBITDA$390.00M
Net income$-7.00M
EPS (TTM)$0.16
Free cash flow$700.25M
Total cash$8.92B
Total debt$3.95B
Book value / share$80.21
Shares outstanding52.20M
Float46.01M
Short % of float6.54%
Dividend yield—
Beta (5Y)0.75
Valuation & profitability ratios
Trailing P/E1,251.81
Forward P/E20.56
PEG ratio1.81
Price / sales—
Price / book2.50
EV / revenue0.13
EV / EBITDA14.09
Gross margin8.43%
Operating margin1.40%
Profit margin-0.02%
Return on equity-0.16%
Return on assets1.16%
Debt / equity94.77
Current ratio1.68
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $45.43B | $40.65B | $34.07B | $31.97B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $472.00M | $1.18B | $1.09B | $792.00M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $472.00M | $1.18B | $1.09B | $792.00M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.40 | 1.51 | +7.8% |
| Mar 2026 | 1.91 | 2.35 | +23.0% |
| Dec 2025 | 0.33 | -2.75 | -921.5% |
| Sep 2025 | 3.89 | 1.84 | -52.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.83 | 18 | $10.86B | -5.4% |
| Next quarter | 0.29 | 5 | $11.91B | +4.7% |
| Current year | 5.24 | 19 | $44.44B | -2.2% |
| Next year | 8.55 | 6 | $48.08B | +8.2% |
Analyst targets & ownership
Mean target$209.12
High target$266.00
Low target$147.00
Implied upside3.42%
Analyst count17
ConsensusNONE
Strong buy / Buy0 / 3
Hold15
Sell / Strong sell0 / 1
Held by insiders1.42%
Held by institutions111.58%
Institutions holding801
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+122.47K
Net buying
Buy transactions
27
141.39K shares
Sell transactions
3
18.92K shares
Net transactions
+30
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
741.24K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 1, 26 | ORLANDO STEVEN J Director |
STOCK | 237 | $55.11K | Indirect |
| Jul 1, 26 | WOLF DALE B Director |
STOCK | 237 | $55.11K | Indirect |
| Jul 1, 26 | SCHAPIRO RICHARD M Director |
STOCK | 237 | $55.11K | Direct |
| Jul 1, 26 | LOCKHART STEPHEN H Director |
STOCK | 237 | $55.11K | Direct |
| Jul 1, 26 | ROMNEY RONNA E Director |
STOCK | 237 | $55.11K | Indirect |
| Jul 1, 26 | BRASIER BARBARA L. Director |
STOCK | 237 | $55.11K | Direct |
| Jul 1, 26 | SOISTMAN FRANCIS S JR Director |
STOCK | 237 | $55.11K | Direct |
| Jul 1, 26 | ZORETIC RICHARD C Director |
STOCK | 237 | $55.11K | Indirect |
| Jul 1, 26 | GROHOWSKI LEO P Director |
STOCK | 237 | $55.11K | Direct |
| Jun 30, 26 | BACON DEBRA Officer |
STOCK | 23 | $5.26K | Direct |
| Jun 30, 26 | BARLOW JEFF D Officer |
STOCK | 138 | $31.56K | Direct |
| Jun 30, 26 | WOYS JAMES E Chief Operating Officer |
STOCK | 144 | $32.93K | Direct |
| May 14, 26 | HEBERT MAURICE S Officer |
SELL | 600 | $114.93K | Direct |
| May 11, 26 | BARLOW JEFF D Officer |
SELL | 17.81K | $3.31M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BACON DEBRA |
Officer | 21.64K | Stock Award(Grant) |
BARLOW JEFF D |
Officer | 67.31K | Stock Award(Grant) |
HEBERT MAURICE S |
Officer | 12.81K | Sale |
KEIM MARK LOWELL |
Chief Financial Officer | 83.25K | Stock Award(Grant) |
ORLANDO STEVEN J |
Director | — | Stock Award(Grant) |
ROMNEY RONNA E |
Director | — | Stock Award(Grant) |
WOLF DALE B |
Director | — | Stock Award(Grant) |
WOYS JAMES E |
Chief Operating Officer | 90.18K | Stock Award(Grant) |
ZUBRETSKY JOSEPH M |
Chief Executive Officer | — | Sale |
ZUBRETSKY JOSEPH M. |
Chief Executive Officer | 356.73K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
202.26
-0.03% from price
SMA 20
199.07
+0.61% from price
SMA 50
210.61
-4.90% from price
SMA 100
192.15
+5.23% from price
SMA 200
174.54
+14.76% from price
EMA 12
201.47
+0.36% from price
EMA 26
203.85
-0.81% from price
EMA 50
203.18
-0.48% from price
RSI (14)
46.6
Neutral
MACD (12,26,9)
-2.38
Hist 0.53
ATR (14)
7.10
3.54% of price
Realised vol 30D
45.9%
Annualised
Bollinger upper
209.30
20, 2σ
Bollinger lower
188.84
20, 2σ
50 / 200 cross
Golden
210.61 vs 174.54
Trend bias
Above 200
+14.76%
Risk profile
Beta vs SPY
-0.13
Less volatile than market
Correlation to SPY
-0.03
Largely independent
Realised vol 30D
45.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-39.7%
Peak to trough
Max drawdown 5Y
-70.8%
Peak to trough
ATR 14
7.10
3.54% of price
Beta (reported)
0.75
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
4.03
Put-heavy session
Put / call open interest
2.21
Positioning, not flow
Max pain
190.00
-5.1% from spot
ATM implied vol
43.2%
Nearest strike to spot
Skew (10% OTM)
-7.2%
Calls bid over puts
Call volume
327
Contracts, this expiry
Put volume
1.32K
Contracts, this expiry
Heaviest call OI
190.00
252 contracts
Heaviest put OI
150.00
1.01K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Molina (MOH) Down 1.7% Since Last Earnings Report: Can It Rebound?
Zacks · 23h ago
Molina Healthcare (MOH) Surged on Medicaid Clarity and Robust Results
Insider Monkey · 9d ago
'Big Short' Investor Michael Burry Doubles Down on This Health Care Stock
GuruFocus.com · 9d ago
Michael Burry adds to Nvidia and Palantir shorts while loading up on Molina Healthcare, which is down 54% from its high
Moneywise · 10d ago
2 Cash-Heavy Stocks on Our Watchlist and 1 We Avoid
StockStory · 10d ago
Michael Burry Adds To NVDA, PLTR, ORCL Shorts — Why He’s Thinking About 2005 Again
Stocktwits · 11d ago
Health insurers are dumping Medicare Advantage plans. Here’s how many seniors could be affected.
MarketWatch · 11d ago
UnitedHealth's Cost-Control Story is Gaining Momentum: Time to Buy?
Zacks · 24d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.